Uremic pruritus, dialysis adequacy, and metabolic profiles in hemodialysis patients: a prospective 5-year cohort study

Mei-Ju Ko, Hon-Yen Wu, Hung-Yuan Chen, Yen-Ling Chiu, Shih-Ping Hsu, Mei-Fen Pai, Ju-Yehyang, Chun-Fu Lai, Hui-Min Lu, Shu-Chen Huang, Shao-Yu Yang, Su-Yin Wen, Hsien-Ching Chiu, Fu-Chang Hu, Yu-Sen Peng, Shiou-Hwa Jee, Mei-Ju Ko, Hon-Yen Wu, Hung-Yuan Chen, Yen-Ling Chiu, Shih-Ping Hsu, Mei-Fen Pai, Ju-Yehyang, Chun-Fu Lai, Hui-Min Lu, Shu-Chen Huang, Shao-Yu Yang, Su-Yin Wen, Hsien-Ching Chiu, Fu-Chang Hu, Yu-Sen Peng, Shiou-Hwa Jee

Abstract

Background: Uremic pruritus is a common and intractable symptom in patients on chronic hemodialysis, but factors associated with the severity of pruritus remain unclear. This study aimed to explore the associations of metabolic factors and dialysis adequacy with the aggravation of pruritus.

Methods: We conducted a 5-year prospective cohort study on patients with maintenance hemodialysis. A visual analogue scale (VAS) was used to assess the intensity of pruritus. Patient demographic and clinical characteristics, laboratory parameters, dialysis adequacy (assessed by Kt/V), and pruritus intensity were recorded at baseline and follow-up. Change score analysis of the difference score of VAS between baseline and follow-up was performed using multiple linear regression models. The optimal threshold of Kt/V, which is associated with the aggravation of uremic pruritus, was determined by generalized additive models and receiver operating characteristic analysis.

Results: A total of 111 patients completed the study. Linear regression analysis showed that lower Kt/V and use of low-flux dialyzer were significantly associated with the aggravation of pruritus after adjusting for the baseline pruritus intensity and a variety of confounding factors. The optimal threshold value of Kt/V for pruritus was 1.5 suggested by both generalized additive models and receiver operating characteristic analysis.

Conclusions: Hemodialysis with the target of Kt/V ≥1.5 and use of high-flux dialyzer may reduce the intensity of pruritus in patients on chronic hemodialysis. Further clinical trials are required to determine the optimal dialysis dose and regimen for uremic pruritus.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Histogram and density plot of…
Figure 1. Histogram and density plot of visual analogue scale (VAS) scores.
(A) Frequency distribution of pruritus VAS scores at baseline in the study participants. (B) Frequency distribution of pruritus VAS scores at follow-up in the study participants. The density of vertical axis represents the percentage of study participants.
Figure 2. Histogram and density plot of…
Figure 2. Histogram and density plot of visual analogue scale (VAS) change scores.
Frequency distribution of pruritus VAS change scores in the study participants. The density of vertical axis represents the percentage of study participants. The VAS change score = VAS score at follow-up − VAS score at baseline.
Figure 3. Identifying the appropriate threshold of…
Figure 3. Identifying the appropriate threshold of baseline Kt/V by the generalized additive models (GAM) plot.
(A) The GAM plot adjusted for the important covariates at baseline only (gender, Kt/V, use of high-flux dialyzer, pruritus intensity, hematocrit, creatinine, uric acid, fasting glucose, total bilirubin, and Ca×P).(B) The GAM plot adjusted for the important covariates at baseline (Kt/V, pruritus intensity, AST, and Ca×P) and the change scores of the covariates (uric acid, fasting glucose, and AST). The solid red lines show nonlinearity of multivariable-adjusted relation between baseline Kt/V and change score of pruritus (with 95% confidence intervals shown in black dotted lines). Pruritus intensity was assessed by visual analog scale scores. The little vertical bars (i.e., rugs) on the horizontal axis of the GAM plots display the distribution of individual observations. Both GAM plots identified the value around 1.5 to be the appropriate threshold of baseline Kt/V for uremic pruritus, which indicated start of the aggravation of pruritus intensity began at Kt/V

References

    1. Mathur VS, Lindberg J, Germain M, Block G, Tumlin J, et al. (2010) A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol 5: 1410–1419.
    1. Pisoni RL, Wikstrom B, Elder SJ, Akizawa T, Asano Y, et al. (2006) Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 21: 3495–3505.
    1. Duque MI, Thevarajah S, Chan YH, Tuttle AB, Freedman BI, et al. (2006) Uremic pruritus is associated with higher kt/V and serum calcium concentration. Clin Nephrol 66: 184–191.
    1. Hiroshige K, Kabashima N, Takasugi M, Kuroiwa A (1995) Optimal dialysis improves uremic pruritus. Am J Kidney Dis 25: 413–419.
    1. Morton CA, Lafferty M, Hau C, Henderson I, Jones M, et al. (1996) Pruritus and skin hydration during dialysis. Nephrol Dial Transplant 11: 2031–2036.
    1. Massry SG, Popovtzer MM, Coburn JW, Makoff DL, Maxwell MH, et al. (1968) Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disappearance of itching after subtotal parathyroidectomy. N Engl J Med 279: 697–700.
    1. Graf H, Kovarik J, Stummvoll HK, Wolf A (1979) Disappearance of uraemic pruritus after lowering dialysate magnesium concentration. Br Med J 2: 1478–1479.
    1. Narita I, Alchi B, Omori K, Sato F, Ajiro J, et al. (2006) Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 69: 1626–1632.
    1. Chiu YL, Chen HY, Chuang YF, Hsu SP, Lai CF, et al. (2008) Association of uraemic pruritus with inflammation and hepatitis infection in haemodialysis patients. Nephrol Dial Transplant 23: 3685–3689.
    1. Kaysen GA (2001) The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 12: 1549–1557.
    1. Wikstrom B, Gellert R, Ladefoged SD, Danda Y, Akai M, et al. (2005) Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 16: 3742–3747.
    1. Peer G, Kivity S, Agami O, Fireman E, Silverberg D, et al. (1996) Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 348: 1552–1554.
    1. Chen HY, Chiu YL, Hsu SP, Pai MF, Lai CF, et al. (2010) Elevated C-reactive protein level in hemodialysis patients with moderate/severe uremic pruritus: a potential mediator of high overall mortality. QJM 103: 837–846.
    1. Ko MJ, Yang JY, Wu HY, Hu FC, Chen SI, et al. (2011) Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. Br J Dermatol 165: 633–639.
    1. Pauli-Magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, et al. (2000) Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 11: 514–519.
    1. Yosipovitch G, Zucker I, Boner G, Gafter U, Shapira Y, et al. (2001) A questionnaire for the assessment of pruritus: validation in uremic patients. Acta Derm Venereol 81: 108–111.
    1. Hemodialysis Adequacy 2006 Work Group (2006) Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 48 Suppl 1S2–90.
    1. Daugirdas JT (1995) Simplified equations for monitoring Kt/V, PCRn, eKt/V, and ePCRn. Adv Ren Replace Ther 2: 295–304.
    1. Clarke PS (2004) Causal Analysis of Individual Change Using the Difference Score. Epidemiology 15: 414–421.
    1. Ware JH (1985) Linear models for the analysis of longitudinal studies. The American Statistician 39(2): 95–101.
    1. Benedetti A, Abrahamowicz M, Leffondré K, Goldberg MS, Tamblyn R (2009) Using Generalized Additive Models to Detect and Estimate Threshold Associations. The International Journal of Biostatistics 5.
    1. Yee TW (2012) VGAM: Vector generalized linear and additive models. R package, version 0.9–0.
    1. Yee TW, Wild CJ (1996) Vector generalized additive models. Journal of the Royal Statistical Society Series B-Methodological 58: 481–493.
    1. Hastie T, Tibshirani R (1990) The gam Package. London: Chapman and Hall.
    1. Hastie TJ, Tibshirani R (1991) Generalized additive models. Chapter 7 of Statistical Models in S eds J M Chambers and T J Hastie, Pacific Grove, CA: Wadsworth & Brooks/Cole.
    1. Youden WJ (1950) Index for rating diagnostic tests. Cancer 3: 32–35.
    1. Dyachenko P, Shustak A, Rozenman D (2006) Hemodialysis-related pruritus and associated cutaneous manifestations. Int J Dermatol 45: 664–667.
    1. Zucker I, Yosipovitch G, David M, Gafter U, Boner G (2003) Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol 49: 842–846.
    1. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, et al. (2002) Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347: 2010–2019.
    1. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, et al. (2010) In-center hemodialysis six times per week versus three times per week. N Engl J Med 363: 2287–2300.
    1. Owen WF Jr, Chertow GM, Lazarus JM, Lowrie EG (1998) Dose of hemodialysis and survival: differences by race and sex. JAMA 280: 1764–1768.
    1. Port FK, Ashby VB, Dhingra RK, Roys EC, Wolfe RA (2002) Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 13: 1061–1066.
    1. Wolfe RA, Ashby VB, Daugirdas JT, Agodoa LY, Jones CA, et al. (2000) Body size, dose of hemodialysis, and mortality. Am J Kidney Dis 35: 80–88.
    1. Narita I, Iguchi S, Omori K, Gejyo F (2008) Uremic pruritus in chronic hemodialysis patients. J Nephrol 21: 161–165.
    1. Masi CM, Cohen EP (1992) Dialysis efficacy and itching in renal failure. Nephron 62: 257–261.
    1. Seres DS, Strain GW, Hashim SA, Goldberg IJ, Levin NW (1993) Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol 3: 1409–1415.
    1. van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J (1991) Effect of dialysis membrane and patient’s age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int 39: 1012–1019.
    1. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, et al. (1997) Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 52: 1096–1101.
    1. Mistik S, Utas S, Ferahbas A, Tokgoz B, Unsal G, et al. (2006) An epidemiology study of patients with uremic pruritus. J Eur Acad Dermatol Venereol 20: 672–678.

Source: PubMed

3
Sottoscrivi